HC Wainwright Forecasts Armata Pharmaceuticals FY2026 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Equities research analysts at HC Wainwright issued their FY2026 EPS estimates for Armata Pharmaceuticals in a research report issued on Thursday, May 14th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($1.88) for the year. HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN ARMP opened at $7.60 on Tuesday. The business has a 50 day moving average price of $10.30 and a 200 day moving average price of $8.18. The company has a market capitalization of $279.00 million, a P/E ratio of -0.98 and a beta of 1.31. Armata Pharmaceuticals has a 1-year low of $1.17 and a 1-year high of $16.34.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Armata Pharmaceuticals by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock worth $690,000 after buying an additional 5,342 shares in the last quarter. SeaCrest Wealth Management LLC increased its holdings in Armata Pharmaceuticals by 17.3% during the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares in the last quarter. State Street Corp raised its position in Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter valued at about $108,000. Finally, Millennium Management LLC purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter valued at about $164,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.